What is the current stock price of Jade Biosciences, Inc. (JBIO)?

As of the latest market data, Jade Biosciences, Inc. (JBIO) is trading at $17.89. The stock has seen a loss of -1.87% today.

Does Jade Biosciences, Inc. (JBIO) pay a dividend?

Based on current data, Jade Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Jade Biosciences, Inc.?

The current market capitalization of Jade Biosciences, Inc. (JBIO) is approximately unavailable.

JBIO

Jade Biosciences, Inc.·Healthcare

17.89

1.865%(−0.34)

Market Closed

21.68

21.185%(+3.79)

After Hours

Last Updated: — ET

52W L: $6.5752W H: $100.10

JBIO NEWS

globenewswire.com

Mar 6

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the fourth quarter and full year ending December 31, 2025, and provided a corporate update.

seekingalpha.com

Feb 27

Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript

globenewswire.com

Feb 11

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:

seekingalpha.com

Jan 16

Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Profile

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2025-04-29

Beta

1.03

Websitejadebiosciences.com↗